|Home | About | Journals | Submit | Contact Us | Français|
The present study reports on 15 patients with confirmed or suspected secondary fungal infection, who were treated with intravenous miconazole and a daily dose of 0.4 to 28 g (mean 9.8 g). The mycological findings confirmed infection with Aspergillus fumigatus in 6 patients and severe infection with Candida albicans in 4. Clinically mycological cures were achieved in 4 patients and some improvement was found in 3 others. The excellent patient tolerance of the drug makes it seem a likely treatment not only for patients with mycologically confirmed infection but also for those whose condition exposes them to a high risk of fungal infection.